Founder and executive insider buying signals deep mispricing across selected equities

Conviction: 77% · Horizon: 12M · 2026-05-07
Insperity may be materially undervalued after a severe drawdown and repeated founder accumulation

A founder-led company buying heavily after a collapse can indicate that the market is over-discounting temporary pressure and underestimating earnings recovery potential.

Instrument Side Target Reason
NSP Long We believe the market may be extrapolating short-term weakness too far, while aligned founder capital suggests confidence in normalization, durable cash generation, and a materially higher intrinsic value.
Sportradar offers asymmetric upside if sports data and betting infrastructure remain structurally underappreciated

A scaled data and technology platform embedded in sports betting ecosystems can compound through rising wagering activity, sticky customer relationships, and operating leverage.

Instrument Side Target Reason
SRAD Long We believe a critical sports data supplier with expanding product depth and embedded distribution can capture durable growth, while current valuation may not fully reflect its strategic position and margin potential.
Telix can benefit from sustained growth in radiopharmaceutical oncology

An oncology platform with approved products and exposure to a fast-growing treatment category can compound as adoption broadens and additional indications expand the revenue base.

Instrument Side Target Reason
TLX.AX Long We believe radiopharmaceutical oncology remains early in its adoption curve, and a company with commercial traction and product pipeline optionality can grow faster than the market currently prices.

Themes

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.